ZyVersa Therapeutics Q2 EPS $(3.31) Beats $(3.75) Estimate
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics (NASDAQ:ZVSA) reported a Q2 EPS of $(3.31), beating the analyst consensus estimate of $(3.75) by 11.73%. This represents a significant improvement over the same period last year.
August 09, 2024 | 8:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ZyVersa Therapeutics reported a Q2 EPS of $(3.31), beating the analyst consensus estimate of $(3.75) by 11.73%. This is a significant improvement over the same period last year.
The better-than-expected EPS indicates that ZyVersa Therapeutics is performing better than analysts anticipated, which is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100